Graduate Management Admission Council Welcomes New Members to the Board

New additions reflect the diverse, global perspective of the business school community

RESTON, Va., June 23, 2021 (GLOBE NEWSWIRE) — The Graduate Management Admission Council™ (GMAC™), a global association of leading graduate business schools, today announced the addition of four new members to its board of directors. Katy Montgomery, Associate Dean, Degree Programmes, INSEAD; François Ortalo-Magné, Dean, London Business School; and Giuseppe Soda, Dean, SDA Bocconi School of Management, Bocconi University, will begin their terms on July 1. In addition, Yuan Ding, Vice President and Dean of China Europe International Business School (CEIBS), was appointed as a board director in January this year to fill the seat vacated by Enase Okonedo of the Pan-Atlantic University.

“GMAC’s new board of directors represent leading business schools with campuses located in 10 countries across Europe, Asia, North America, Africa, and the Middle East,” said Sangeet Chowfla, president and CEO of GMAC. “As student mobility returns and regains in the post-pandemic world, I look forward to working alongside this diverse group of leaders ― and the rest of the GMAC board ― to continue to advance GMAC’s vision to ensure that all talented individuals can benefit from the best business education for them.”

New GMAC Board Members

Yuan Ding, Vice President and Dean, Cathay Capital Chair in Accounting, CEIBS

Yuan Ding is Vice President and Dean and the Cathay Capital Chair Professor in Accounting at CEIBS, where he has been honored three times with the CEIBS Teaching Excellence Award. Prior to joining CEIBS, he was a tenured faculty member of the HEC School of Management, Paris, France. He is a member of the European Accounting Association, French Accounting Association and American Accounting Association. He holds a PhD in Accounting from the Institute of Enterprises Administration at the University Montesquieu Bordeaux IV, France, as well as a Master’s in Enterprises Administration from the University of Poitiers, France. Ding is the author of multiple books on financial reporting and his research appears in leading academic journals.

Katy Montgomery, Associate Dean, Degree Programmes, INSEAD

As the INSEAD Associate Dean of Degree Programmes, Montgomery is responsible for the commercial leadership of the INSEAD Degree Programme portfolio across four campuses: Fontainebleau, Singapore, Abu Dhabi, and San Francisco. Her functional responsibilities include strategy, marketing, sales, admissions, financial aid and scholarships, programme operations, student life, psychological services, and career services. Prior to joining INSEAD, she served as Associate Dean of Student Development at Johns Hopkins Carey Business School. Montgomery holds a degree in Political Science from Loyola University New Orleans and a Juris Doctor degree from Georgetown University Law Center.

François Ortalo-Magné, Dean, London Business School

François Ortalo-Magné is the ninth Dean of London Business School (LBS), a position he has held since August 2017. He is leading a strategy focused on (1) academic research and its impact, (2) learning innovations and alumni engagement and (3) inclusion, striving for gender parity and greater socio-economic and ethnic diversity. Since taking up the role, Ortalo-Magné has led the relaunch of the LBS brand, the growth of degree programmes and a significant increase in philanthropic support for scholarships. His research on the economics of land and housing markets has been published in leading academic journals. He has built on his research and leadership experiences to advise a broad range of private, governmental and multi-lateral organisations and share his insights in leading media outlets and at conferences around the world. Prior to his appointment, Ortalo-Magné was the Albert O. Nicholas Dean and Robert E. Wangard Professor of Real Estate at the Wisconsin School of Business. His first academic appointment was at the London School of Economics.

Giuseppe Soda, Dean, SDA Bocconi School of Management, Bocconi University

Giuseppe “Beppe” Soda is the Dean of SDA Bocconi School of Management and Full Professor of Organization Theory and Network Analysis at Bocconi University. Before becoming Dean in 2016, his roles have included serving as the Associate Dean for Research (2007-2013), Director of the Department of Management and Technology (2013-2016) and Head of Organization and HRM Department (2001-2006). He is also serving EFMD as member of the EQUIS Accreditation Board. Soda’s research investigates the performance consequences of the interplay between organizational architectures and organizational networks and his work has been published in top academic management journals.

Besides the aforementioned newly elected board members, Martin Boehm, Professor of Marketing and former Dean of IE Business School and soon the new Rector of EBS Universität für Wirtschaft und Recht, and Themin Suwardy, Dean of Postgraduate Professional Programmes, Singapore Management University, were re-elected for a second term.

GMAC also recognizes its outgoing board members, Leila Guerra, Vice Dean (Education) of Imperial College Business School, and Peter Tufano, Peter Moores Dean and Professor of Finance of Saïd Business School, University of Oxford. GMAC thanks them for their service in the past nearly four years to our organization and contributions to the graduate management education community.

About GMAC

The Graduate Management Admission Council™ (GMAC™) is a mission-driven association of leading graduate business schools worldwide. Founded in 1953, GMAC creates solutions and experiences that enable business schools and candidates to better discover, evaluate, and connect with each other.

GMAC provides world-class research, industry conferences, recruiting tools, and assessments for the graduate management education industry, as well as tools, resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test™ (GMAT™) exam is the most widely used graduate business school assessment.

GMAC also owns and administers the NMAT by GMAC™ (NMAT™) exam and the Executive Assessment (EA). More than 7 million candidates on their business master’s or MBA journey visited GMAC’s last year to explore business school options, prepare and register for exams, and get advice on the admissions process. BusinessBecause and The MBA Tour are subsidiaries of GMAC, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
202-390-4180 (mobile)

RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke

MIAMI, June 23, 2021 (GLOBE NEWSWIRE) — RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15 million Series A financing. The financing was led by Santé Ventures who was joined by Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon. RapidPulse plans to use the proceeds to advance its RapidPulse™ Cyclic Aspiration System through expanded clinical evaluation and build out its platform of proprietary catheters.

The RapidPulse™ system was developed by Syntheon, a medical device incubator focused on developing next generation medical devices. Their various products, commercialized by the largest and most trusted medical device companies in the world, have treated over 50 million patients globally in applications ranging from laparoscopic surgery, cardiovascular, and flexible endoscopy. Syntheon has over 200 issued patents since its inception over 20 years ago.

“We are pleased to have partnered with an outstanding investor syndicate to move our RapidPulse™ technology forward in the clinic,” said Sean McBrayer, CEO of Syntheon who will also serve as initial CEO of RapidPulse. “Stroke is the second leading cause of death and the third leading cause of disability worldwide, and minutes matter in improving these outcomes. This investment will help us expand our clinical results and move towards regulatory approval in the United States.”

Joining the team are industry veterans Heather Harries and Cynthia Yang. Heather most recently served as General Manager for Terumo’s aortic business and will lead product development and operations for RapidPulse. Cynthia will lead clinical development for the company, after most recently working in the neurovascular division of Medtronic.

Dennis McWilliams, partner at Santé Ventures, added, “Heather and Cynthia bring exceptional domain expertise to the team at RapidPulse, and will complement the significant engineering development experience at Syntheon. RapidPulse is a disruptive platform opportunity in neurovascular, and has the potential to significantly improve patient outcomes for ischemic stroke patients.”


RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry. Visit for more information.


Santé Ventures is a life sciences investment firm that invests in early-stage companies in medical device, biotechnology, and digitally enabled health services. We partner with entrepreneurs to build impactful companies, including Claret Medical (now part of Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), and Molecular Templates (NASDAQ: MTEM). Founded in 2006, Santé has just under $1 billion in assets under management, and has offices in Austin, TX and Boston, MA. For more information, please visit


Epidarex Capital is a transatlantic venture capital firm that builds exceptional life science companies in emerging hubs in the US and UK. Epidarex’s experienced team of early-stage investors partner with entrepreneurs and leading research institutions to transform world-class science into highly innovative products addressing major unmet needs in global healthcare. For more information, please visit


Founded in 2000 and based in Durham, NC, Hatteras Venture Partners is a venture capital firm with a focus on seed and early stage healthcare investing. Through six funds and over $600 million under management, the firm has invested in breakthrough science and entrepreneurial grit in the areas of biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. To learn more, please visit


Founded in 2008, Broadview Ventures is a mission-driven investment organization. Broadview’s primary goal is to improve human health in the areas of cardiovascular disease and stroke through investments in early stage companies developing innovative therapeutics, devices, and diagnostics. For more information about Broadview Ventures, visit


Sean McBrayer,, 305-266-3388

WillScot Mobile Mini Announces Pricing of Secondary Offering

PHOENIX, June 23, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a North American leader in modular space and portable storage solutions, today announced the pricing of its previously announced underwritten, secondary offering (the “Offering”) of 14,000,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Shares have been offered by the Company’s principal shareholder, Sapphire Holding S.à r.l., an entity controlled by TDR Capital (the “Selling Stockholder”), at a price to the public of $27.95 per share. The Selling Stockholder granted the underwriter a 30-day option to purchase up to an additional 2,100,000 shares. The Company has not offered any shares in the Offering and will not receive any of the proceeds from the Offering. The closing of the Offering is expected to occur on June 25, 2021.

Morgan Stanley has acted as sole underwriter for the Offering.

The Offering is being made pursuant to an effective shelf registration statement, including a base prospectus, that has been filed with the Securities and Exchange Commission (the “SEC”) and became automatically effective on March 1, 2021 and is available on the SEC’s website. A preliminary prospectus supplement and the accompanying base prospectus related to the Offering were filed with the SEC on June 23, 2021 and are available on the SEC’s website. Copies of these documents may be obtained from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department.

In addition, the Company has entered into a share repurchase agreement with the Selling Stockholder pursuant to which it will repurchase 3,900,000 shares of Common Stock directly from the Selling Stockholder (the “Share Repurchase”). The price per share to be paid by the Company will be equal to the price per Share paid by the underwriters for the Shares in the Offering. The Company expects to fund the Share Repurchase from borrowings under its ABL Credit Facility. The Share Repurchase is expected to be consummated concurrently with the closing of the Offering. Although the Share Repurchase is conditioned upon the closing of the Offering, the closing of the Offering is not conditioned upon the closing of the Share Repurchase.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company, nor shall there be any sale of securities of the Company in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Certain of these forward-looking statements include statements relating to the timing and conduct of the Offering, the size and terms of the Offering and the closing of the Offering. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. These risks include, without limitation, risks and uncertainties related to market conditions, that the size of the Offering could change or the Offering could be terminated, and the satisfaction of customary closing conditions related to the Offering. Any forward-looking statement speaks only at the date which it is made, and WillScot Mobile Mini disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About WillScot Mobile Mini Holdings Corp.

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible workspace and portable storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 275 branch locations and additional drop lots throughout the United States, Canada, Mexico, and the United Kingdom.

Contact Information

Investor Inquiries:

Nick Girardi

Media Inquiries:

Scott Junk

Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facility

TEL AVIV, Israel and SEATTLE, Wash., June 23, 2021 (GLOBE NEWSWIRE) — Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA (NASH). Under terms of the agreement, the companies will work together to optimize, upscale and lock the CM-101 manufacturing process towards its testing in pivotal studies while AGC Biologics will manufacture the clinical trial materials at its site in Copenhagen, to support phase II/III clinical testing and launch readiness.

“AGC is a high-quality partner with global manufacturing expertise, and we are pleased to extend our long-standing relationship as we continue to progress in our clinical development,” said Adi Mor, Chief Executive Officer. “CM-101 has tremendous potential in treating fibrosis and inflammation, and we are excited to continue to scale up our manufacturing capacity ahead of our Phase 3 registration-enabling trials.”

Mark Womack, Chief Business Officer at AGC Biologics added, “We are very pleased that Chemomab has entrusted us to manufacture CM-101, following successful delivery of the early phase supply. Our Copenhagen site has the proven experience and expertise to help Chemomab in its journey towards market supply of this important therapy.”

“The Copenhagen team is excited to help advance the manufacturing process for CM-101 to the next phase, and is looking forward to a close collaboration with the Chemomab team,” says AGC Biologics General Manager, Copenhagen, Andrea C. Porchia.

AGC Biologics’ Copenhagen facility has over 20 years’ experience delivering a wide range of mammalian and microbial programs, including several commercially approved products. The news comes less than seven months after the announcement of a €160M expansion project that would double the production capacity in Denmark to address increasing market demand.

About CM-101 
CM-101 is a first-in-class monoclonal antibody that targets CCL24 and has been shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.  Pre-clinical evidence has shown CM-101 to be an effective therapy with potential to fill the gap in today’s fibrotic disease care. CM-101 has been well-tolerated in healthy subjects and in NAFLD patients via intravenous or subcutaneous administrations. Both routes of administration support long dosing intervals and provide evidence of target engagement and biological activity in humans. CM-101 Phase 2 safety and efficacy trials in patients with PSC and Liver fibrosis (NASH) are currently ongoing and a third Ph2, in Systemic sclerosis, is expected to initiate by the end of 2021.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to deliver the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our global network spans the U.S., Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 1,700 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit

About Chemomab Therapeutics Ltd. 
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc).
For more information on Chemomab, please visit

Forward Looking Statements 
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab’s current expectations. Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on Chemomab’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation, including: the uncertain and time-consuming regulatory approval process; risks related to Chemomab’s ability to correctly manage its operating expenses and its expenses; Chemomab’s plans to develop and commercialize its product candidates, focusing on CM-101; the timing of initiation of Chemomab’s planned clinical trials; the timing of the availability of data from Chemomab’s clinical trials; the timing of any planned investigational new drug application or new drug application; Chemomab’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Chemomab’s product candidates; Chemomab’s commercialization, marketing and manufacturing capabilities and strategy; Chemomab’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all. Additional risks and uncertainties relating to Chemomab’s and its business can be found under the caption “Risk Factors” and elsewhere in Chemomab’s filings and reports with the SEC. Chemomab expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

AGC Biologics Contact:
Media Contact: Matteo Pellegrino

Chemomab Therapeutics Ltd.

Investor Relations:
Irina Koffler
LifeSci Advisor, LLC
Phone: +1-917-734-7387

Chemomab Therapeutics:
Sharon Elkobi 
VP, Business Development
Phone: +972773310156

Matteo Pellegrino
AGC Biologics

Conformis, Inc. Announces Exclusive Distribution Agreement in China

New Agreement expands Conformis’ global reach and brings patient-specific knee replacement systems to the largest market in the Asia-Pacific region

BILLERICA, Mass., June 23, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) today announced the execution of an agreement to enter the Asia-Pacific market through an exclusive distribution relationship with XR Medical Group (Hong Kong) Limited (XR Medical).

Under the distribution agreement, XR Medical will have exclusive rights for the sale, marketing, and distribution of Conformis’ patient-specific iTotal® CR & PS total knee replacement systems, iTotal® CR & PS patella devices, and iUni® and iDuo® partial knee replacement systems. Other products, such as Conformis’ recently approved Identity Imprint™ knee system and its hip portfolio of products, may be added in the future.

XR Medical’s sales team will provide sales and support exclusively to top-tier facilities in Hainan’s Boao Lecheng International Medical Tourism Pilot Zone (Pilot Zone) on behalf of Conformis. The region is a major center of medical tourism for dozens of countries.

“This distribution agreement is another example of progress as we execute our overall growth strategy. We are confident that our unique product portfolio will serve to accelerate Conformis’ international growth. And we are pleased to partner with XR Medical, which has an impressive track record of success in China,” said Mark Augusti, President and CEO of Conformis. “What is particularly attractive about XR Medical is its strong performance in the Pilot Zone. With access to patients visiting the region for treatment, this creates an opportunity to introduce a broad audience to the clinical benefits of Conformis technology. We believe that starting in the Pilot Zone positions us well and we anticipate that this relationship will serve as a model for future expansion opportunities in mainland China.”

The Pilot Zone is located on Hainan, a large island off China’s southern coast. It was established in 2019 to attract affluent Chinese citizens who might otherwise go abroad for their medical care. This region of China has developed top-level medical treatment facilities in a popular destination. Currently, medical tourists from dozens of countries, including those in Southeast Asia, are permitted to visit Hainan for a 30-day stay without visas.

The global market for knee joint reconstruction is projected at more than $9 billion. Of this total, the knee joint reconstruction market in the Asia-Pacific region is currently estimated to exceed $1.7 billion. Fortune Business Insights predicts a high growth rate for knee replacements in the region due to the combination of the increased prevalence of knee disorders, booming medical tourism, increased disposable incomes, and improved healthcare infrastructure.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and standard implants, along with single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal® CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit To receive future releases in e-mail alerts, sign up at

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. You should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Source: Conformis, Inc.

Media Contact:
Investor Relations
(781) 374-5598

Liquid Instruments Introduces Moku:Pro – A High Performance, Software-Defined Instrumentation Platform for Engineers and Scientists

New architecture delivers nine instruments with real-time measurement capabilities to the research lab

Moku:Pro In Lab Setting

Moku:Pro brings test and measurement into the modern age, allowing engineers and researchers to dynamically switch between instruments rather than needing multiple stand-alone devices.

CANBERRA, Australia and SAN DIEGO, June 23, 2021 (GLOBE NEWSWIRE) — Liquid Instruments, an innovator in precision software-defined instrumentation, today announced Moku:Pro, a high-performance platform for engineering and research labs.

Moku:Pro accelerates the transition from traditional fixed-function test and measurement hardware to a flexible field-programmable gate array (FPGA)-based approach by making high-quality instruments accessible in an integrated, software-upgradeable platform.

“Researchers in engineering and physics face constantly evolving requirements – with changes occurring on timescales much shorter than the lifespan of test equipment,” said Daniel Shaddock, CEO of Liquid Instruments. “Moku:Pro’s software-enabled-hardware architecture allows it to evolve as your applications evolve, something that is simply not possible with conventional test equipment.”

Moku:Pro hosts nine powerful instruments, including an oscilloscope, lock-in amplifier, PID controller, phasemeter, arbitrary waveform generator, data logger, spectrum analyzer, frequency response analyzer, and waveform generator to ensure researchers have the instrumentation they need to quickly characterize their set up and scale their experiments. The platform was designed to meet the needs of researchers in a variety of fields, from aerospace to semiconductor. Moku:Pro’s instrument suite is particularly suited to photonics applications, including spectroscopy, microscopy, metrology, gravitational wave detection, active laser stabilization, and quantum computing.


Moku:Pro accelerates the transition from traditional fixed-function test and measurement hardware to a flexible field-programmable gate array (FPGA)-based approach by making high-quality instruments accessible in an integrated, software-upgradeable platform.

“Quantum computing pushes the performance limits of electronics, optics, and flexible real-time signal processing. We see software-defined instrumentation as the future of test and measurement systems for quantum computing,” said Andrew Horsley, CEO and Co-founder of Quantum Brilliance, a full-stack quantum computing company working on room temperature diamond technology.  “Moku:Pro is a workhorse of the lab and one of the most versatile photonics tools we’ve seen.”

Bringing Instrumentation Into the Modern Era
Moku:Pro brings test and measurement into the modern age, allowing engineers and researchers to dynamically switch between instruments rather than needing multiple stand-alone devices.  Advanced ADC blending technology ensures that each instrument can function with optimal sensitivity from RF to acoustic frequencies without compromising performance for flexibility. Full connectivity via Wi-Fi, Ethernet, and USB-C ensures industry-standard, hassle-free configuration.

A key benefit of software-defined instrumentation is that it gets better over time. Moku:Pro can receive over-the-air updates to deliver improved specifications, new instruments, or entirely new capabilities. Users can expect to see these benefits as soon as September when Liquid Instruments plans to release a feature that will give Moku:Pro the ability to run multiple instruments in conjunction with one another and hot-swap instruments in and out. In this multi-instrument mode, instruments can be combined and connected to form sophisticated signal-processing pipelines. Also slated for September release is a new cloud-based tool that will allow users to directly program Moku:Pro’s FPGA. With this capability, users can implement unique signal processing algorithms and create their own custom instruments, which will further widen the gap with conventional hardware.

Moku:Pro Specifications

  • 4 analog inputs and outputs
  • Blended ADC input (10-bit+18-bit) for low noise, high bandwidth applications
  • Sampling rate of 5 GSa/s (1 channel), 1.25 GSa/s (4 channels)
  • 9 integrated instruments, including a DC-600 MHz lock-in amplifier
  • 120 GB SSD for high-speed onboard storage
  • API support for Python and MATLAB
  • Starting at $12,000 for the base configuration, ranging up to $20,000 for the full suite.

A History of Success 
The Liquid Instruments technical leadership team brings deep expertise in complex measurements with experience from Australian National University, Max Planck Institute, Lockheed Martin, Caltech, and NASA’s Jet Propulsion Laboratory.  Moku:Pro expands the line of software-defined solutions from Moku:Lab, a twelve-instrument platform for research, and, more recently, Moku:Go, a complete and portable lab solution for undergraduate education.

For more information on Moku:Pro, visit:

About Liquid Instruments
Liquid Instruments is a leader in precision software-defined instrumentation and is revolutionizing the way that students, engineers, and scientists learn, work, and discover. Their product line of hardware and software solutions leverages the computational power of modern FPGAs to create highly customizable instrumentation for controlling experiments and acquiring and analyzing data. The team’s IP in software-defined hardware enables Moku products to be dynamically reconfigurable in the field, serving a wide range of ever-changing experimental and process control situations. For more information, visit

The Project received funding from The Australian Government. Liquid Instruments gratefully acknowledges funding and support of the Australian Commonwealth Government through the CRC-P program administered by the Department of Industry Innovation and Science.

Media Contact
Codeword for Liquid Instruments

Photos accompanying this announcement are available at